سعر كولشيوبو Colchiopo‏ 0.6مجم 30 قرص 2026

Colchiopo 0.6 mg 30 film-coated tablets (colchicine), film-coated tablets by Borg Pharmaceutical Industries.

• Patients with renal or hepatic impairment should not be given colchicine together with P-gp inhibitors or strong CYP3A4 inhibitors (including all protease inhibitors except fosamprenavir); life-threatening and fatal toxicity has been reported.International label, same formulation · DailyMed (US National Library of Medicine)

• Fatal overdoses (accidental and intentional) have been reported in adults and children; keep out of reach of children.International label, same formulation · DailyMed (US National Library of Medicine)
• Blood dyscrasias (myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anaemia) have been reported at therapeutic doses.International label, same formulation · DailyMed (US National Library of Medicine)
• Neuromuscular toxicity including rhabdomyolysis may occur, especially with other drugs known to cause this effect.International label, same formulation · DailyMed (US National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, itraconazole, ritonavir) and P-gp inhibitors (e.g. cyclosporine, ranolazine)Significant increase in colchicine levels; fatal toxicity reported; reduce the colchicine dose (FMF maximum 0.6 mg/day) and avoid in renal/hepatic impairment.DailyMed (US National Library of Medicine)
• Moderate CYP3A4 inhibitors (e.g. diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice)Increased colchicine concentration anticipated; neuromuscular toxicity reported with diltiazem and verapamil; FMF maximum 1.2 mg/day.DailyMed (US National Library of Medicine)

• Decades of published human data have not identified drug-associated risks of major birth defects, miscarriage or adverse maternal/fetal outcomes; colchicine crosses the placenta and animal studies show embryofetal toxicity at clinically relevant exposures.International label, same formulation · DailyMed (US National Library of Medicine)
• Colchicine is present in human milk; no adverse events in breastfed infants have been reported in the published literature.International label, same formulation · DailyMed (US National Library of Medicine)

• Colchicine: Disrupts β-tubulin polymerization into microtubules; inhibits neutrophil activation/migration; may interfere with inflammasome/IL-1β.